A randomized, controlled trial of liraglutide for adolescents with obesity
As of December 2024, the FDA approved tirzepatide for treatment of moderate-to-severe obstructive sleep apnea (OSA) in patients with obesity based on the results of two trials
Purity Peptides | UK Research Peptides | Tirzepatide, Retatrutide, GLP-1 Supply
This new trial built on a previous one published in NEJM last fall (I previously reviewed here) for the same indication, but the only difference was the inclusion of people with diabetes
The side effects at lower maintenance doses are typically mild, and the metabolic benefits (improved glucose control, liver fat reduction, cardiovascular risk reduction) persist only as long as the medication is continued
Through Klarity, you can complete this entirely online with same-day appointments